Compare BELFA & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFA | CLDX |
|---|---|---|
| Founded | 1949 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 1994 | 1995 |
| Metric | BELFA | CLDX |
|---|---|---|
| Price | $155.54 | $27.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $352.50 | $63.79 |
| AVG Volume (30 Days) | 73.3K | ★ 723.2K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $491,611,000.00 | $12,743,000.00 |
| Revenue This Year | $24.35 | N/A |
| Revenue Next Year | $12.99 | $410.81 |
| P/E Ratio | $40.02 | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $118.58 | $22.33 |
| 52 Week High | $293.51 | $45.14 |
| Indicator | BELFA | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 38.81 |
| Support Level | N/A | $22.46 |
| Resistance Level | $211.83 | $31.80 |
| Average True Range (ATR) | 10.52 | 1.52 |
| MACD | -0.63 | -0.09 |
| Stochastic Oscillator | 8.55 | 15.98 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.